Nathan Bahary

20.2k citations

186 papers · 6.3k indexed · 1 hit paper · h-index 43

Impact in

Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Oncology 127
- Pancreatic and Hepatic Oncology Research 91
- Colorectal Cancer Treatments and Studies 19
- Cancer Immunotherapy and Biomarkers 17
Cancer Research 46
- Cancer Genomics and Diagnostics 38

Co-authors: Herbert J. Zeh Aatur D. Singhi Leonard I. Zon Amer H. Zureikat Rudolph L. Leibel Melissa E. Hogg Brian A. Boone Mazen S. Zenati
Journals: Journal of Clinical Oncology (47 papers)Annals of Surgical Oncology (21 papers)Annals of Oncology (8 papers)The American Journal of Surgical Pathology (5 papers)Journal of Surgical Oncology (5 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Nathan Bahary

181 papers receiving 6.2k citations

Hit Papers

align trajectories log scale

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma 2017 · 365 citations

Peers

Countries citing papers authored by Nathan Bahary

Since Specialization

Citations

This map shows the geographic impact of Nathan Bahary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Bahary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Bahary more than expected).

Fields of papers citing papers by Nathan Bahary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Bahary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Bahary. The network helps show where Nathan Bahary may publish in the future.

Co-authors

The 25 scholars most cited alongside Nathan Bahary, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nathan Bahary Line = papers co-authored together Nathan Bahary links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Angiotensin system inhibitor use is associated with longer survival in resected pancreatic cancer HPB ·Hao Liu, Catharine Haak, Sonia Lebowitz, Jaisankar Telanseri J, Ibrahim Nassour, Aatur D. Singhi, Nathan Bahary, P Athiramol, Amer H. Zureikat, Alessandro Paniccia	2021	1
2	Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan Frontiers in Oncology ·Kenneth H. Yu, Andrew Hendifar, Olatunji B. Alese, 허승렬, Maen Abdelrahim, Ethan Burns, Gazala Khan, Paul Cockrum, Rachel H. Bhak, Catherine Nguyen, Maral DerSarkissian, Mei Sheng Duh, Nathan Bahary	2021	5
3	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients Clinical Cancer Research ·Herbert J. Zeh, Nathan Bahary, Brian A. Boone, Aatur D. Singhi, Jennifer L. Miller-Ocuin, Daniel P. Normolle, Amer H. Zureikat, Melissa E. Hogg, David L. Bartlett, Kenneth K. Lee, Allan Tsung, J. Wallis Marsh, Pranav Murthy, Daolin Tang, Natalie Seiser, Ravi K. Amaravadi, Virginia Espina, Lance A. Liotta, Michael T. Lotze	2020	170
4	Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma Modern Pathology ·Shira Klein, Douglas J. Hartman, Changqing Ma, James Celebrezze, David Medich, Nathan Bahary, 留雄宮谷内, Liron Pantanowitz, Reetesh K. Pai	2020	29
5	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma Journal of Clinical Oncology ·Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Tara Elisabeth Seery, William Proctor Harris, Darren Sigal, Fadi Braiteh, Paul S. Ritch, Mark M. Zalupski, Nathan Bahary, Paul E. Oberstein, Andrea Wang‐Gillam, Wilson Wu, Dimitrios Chondros, Ping Jiang, Sihem Khelifa, Jie Pu, Carrie Aldrich, Andrew Hendifar Hit paper breakdown →	2017	365
6	An Unexpected Etiology of Pancreatic Panniculitis: A Case Report SHILAP Revista de lepidopterología ·Anna Evans, Aatur D. Singhi, Herbert J. Zeh, Nathan Bahary, Randall E. Brand	2017	3
7	Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma Practical Radiation Oncology ·Siu Cheung 江紹祥, Philip Sutera, Karen M. Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert J. Zeh, Nathan Bahary, Ronald G. Stoller, Dwight E. Heron	2017	34
8	Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA) Annals of Oncology ·Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, Fadi S. Braiteh, Mark M. Zalupski, Nathan Bahary, William Proctor Harris, Jeffrey J. Pu, Carrie Aldrich, Sihem Khelifa, Wilson Wu, Dimitrios Chondros, Ping Jiang, Andrew Hendifar	2017	4
9	PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine Annals of Oncology ·Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, Fadi Braiteh, Mark M. Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Carrie Aldrich, Sihem Khelifa, Wilson Wu, Joaquina Baranda, Ping Jiang, Andrew Hendifar	2017	5
10	Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors Clinical Cancer Research ·Aatur D. Singhi, Ta‐Chiang Liu, Justin L. Roncaioli, Dengfeng Cao, Herbert J. Zeh, Amer H. Zureikat, Allan Tsung, J. Wallis Marsh, Kenneth K. Lee, Melissa E. Hogg, Nathan Bahary, Randall E. Brand, Kevin M. McGrath, Adam Slivka, Kristi L. Cressman, Kimberly Fuhrer, Roderick J. O’Sullivan	2016	165
11	FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Vincent J. Picozzi, J. Marc Pipas, Albert C. Koong, Amato J. Giaccia, Nathan Bahary, Smitha Krishnamurthi, Charles D. Lopez, Peter J. O’Dwyer, Katharina Modelska, Cameron Burns, James Chou, Ming Zhong, Stefan Hemmerich, Dongxia Li, Ewa Carrier, Seth Porter, Thomas B. Neff, Frank H. Valone	2016	8
12	Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis Journal of Gastrointestinal Surgery ·G. Paul Wright, Katherine E. Poruk, Mazen S. Zenati, Jennifer Steve, Nathan Bahary, Melissa E. Hogg, Fayla De Souza Silva, Christopher L. Wolfgang, Herbert J. Zeh, Matthew J. Weiss	2016	65
13	The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma Modern Pathology ·Aatur D. Singhi, Alyssa M. Krasinskas, Haroon A. Choudry, David L. Bartlett, James F. Pingpank, Herbert J. Zeh, Alyssa Luvison, Kimberly Fuhrer, Nathan Bahary, Raja R. Seethala, Sanja Đačić	2015	89
14	The Chemokine Receptors CXCR4/CXCR7 and Their Primary Heterodimeric Ligands CXCL12 and CXCL12/High Mobility Group Box 1 in Pancreatic Cancer Growth and Development Pancreas ·谌一兵, Daolin Tang, Herbert J. Zeh, 宗孝小山, Carolyn J. Anderson, Nathan Bahary, Michael T. Lotze	2015	23
15	Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma Annals of Surgical Oncology ·George Van Buren, Ramesh K. Ramanathan, Alyssa M. Krasinskas, Ryan P. Smith, Gerard Abood, Nathan Bahary, Barry C. Lembersky, Yongli Shuai, Douglas M. Potter, David L. Bartlett, Amer H. Zureikat, Herbert J. Zeh, A. James Moser	2013	36
16	Lynch syndrome–associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach Human Pathology ·Douglas J. Hartman, Randall E. Brand, Elena Yifei Zhao, Nathan Bahary, Beth Dudley, Simion I. Chiosea, Marina N. Nikiforova, Reetesh K. Pai	2013	24
17	Signet Ring Cell Colorectal Carcinoma The American Journal of Surgical Pathology ·Douglas J. Hartman, Marina N. Nikiforova, Daniel T. Chang, Edward Chu, Nathan Bahary, Randall E. Brand, Amer H. Zureikat, Herbert J. Zeh, Haroon A. Choudry, Reetesh K. Pai	2013	38
18	TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC) Annals of Oncology ·Mitesh J. Borad, Shantan Reddy, Nathan Bahary, Hope E. Uronis, Darren Sigal, 和重三吉, William R. Schelman, Joan Stephenson, Cathy Eng, David P. Ryan	2012	3
19	A Critical Role for Calponin 2 in Vascular Development Journal of Biological Chemistry ·Jian Tang, Guang Hu, J Hanai, K. Venkataraman, Yanfeng Lin, Bo Zhang, Jenna L. Galloway, Nathan Bahary, Fatima Faria Ribeiro, Bernard Thisse, Christine Thisse, Jian‐Ping Jin, Leonard I. Zon, Vikas P. Sukhatme	2005	54
20	Characterization of embryonic globin genes of the zebrafish Developmental Biology ·Alison Brownlie, Candace Hersey, Andrew C. Oates, Barry H. Paw, Arnold M. Falick, H. Ewa Witkowska, Jonathan Flint, Douglas R. Higgs, Jason R. Jessen, Nathan Bahary, Hao Zhu, Shuo Lin, Leonard I. Zon	2003	133

About Nathan Bahary

Nathan Bahary is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Hepatology and Cell Biology, having authored 186 papers that have together received 6.3k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (91 papers), Cancer Genomics and Diagnostics (38 papers), Neuroendocrine Tumor Research Advances (22 papers), Renal cell carcinoma treatment (21 papers), Colorectal Cancer Treatments and Studies (19 papers), Cancer Immunotherapy and Biomarkers (17 papers), Zebrafish Biomedical Research Applications (14 papers) and Pancreatitis Pathology and Treatment (13 papers). The work is most often cited by research in Oncology (3.3k citations), Cancer Research (1.5k citations), Cell Biology (1.0k citations), Immunology (740 citations) and Epidemiology (1.2k citations). Nathan Bahary has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Herbert J. Zeh, Aatur D. Singhi, Leonard I. Zon, Amer H. Zureikat, Rudolph L. Leibel, Melissa E. Hogg, Brian A. Boone, Mazen S. Zenati, Jeffrey M. Friedman and Randall E. Brand. Their work appears in journals such as Journal of Clinical Oncology, Annals of Surgical Oncology, Annals of Oncology, The American Journal of Surgical Pathology and Journal of Surgical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact